Question: In children with osteogenesis imperfecta, is daily
olpadronate therapy better than placebo in reducing fractures?Design: Randomized (allocation concealed), blinded (clinicians,
patients, and outcome assessors), placebo-controlled trial with 2-year
follow-up.Setting: A university medical center in Utrecht, The
Netherlands.Patients: 34 children, 3 to 18 years of age (mean age, 10 y, 53%
girls), with osteogenesis imperfecta with restricted ambulation (maximum
walking distance, 250 m). Follow-up was complete.